Skip to content
Menu

D. Boral Capital Maintains Buy on NeuroSense Therapeutics, Maintains $14 Price Target

Benzinga Newsdesk 10 months ago

NewsPrice TargetAnalyst Ratings

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

D. Boral Capital analyst Jason Kolbert maintains NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy and maintains $14 price target.

D. Boral Capital analyst Jason Kolbert maintains NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy and maintains $14 price target.

Read at benzinga.com